Potent anti-inflammatory activity of the lectin-like domain of TNF in joints

Ana Carolina Matias Dinelly Pinto1, Rodolfo de Melo Nunes1, Igor Albuquerque Nogueira1, Bernhard Fischer2, Rudolf Lucas3, Virgínia Claudia Carneiro Girão-Carmona4, Vivian Louise Soares de Oliveira5, Flavio Almeida Amaral5, Georg Schett6 and Francisco Airton Castro Rocha1*

1Departamento de Medicina Interna, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, Brazil, 2Apeptico Forschung und Entwicklung, Vienna, Austria, 3Vascular Biology Center, Department of Pharmacology and Toxicology, Division of Pulmonary and Critical Care Medicine, Medical College of Georgia at Augusta University, Augusta, GA, United States, 4Departamento de Morfologia, Faculdade de Medicina, Universidade Federal do Ceará, Fortaleza, Brazil, 5Departamento de Bioquímica e Imunologia, Universidade Federal de Minas Gerais, Belo Horizonte, Brazil, 6Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander-University Erlangen-Nürnberg, Erlangen, Germany

In view of the crucial role of tumor necrosis factor (TNF) in joint destruction, TNF inhibitors, including neutralizing anti-TNF antibodies and soluble TNF receptor constructs, are commonly used therapeutics for the treatment of arthropathies like rheumatoid arthritis (RA). However, not all patients achieve remission; moreover, there is a risk of increased susceptibility to infection with these agents. Spatially distinct from its receptor binding sites, TNF harbors a lectin-like domain, which exerts unique functions that can be mimicked by the 17 residue solnatide peptide. This domain binds to specific oligosaccharides such as N′N′-diacetylchitobiose and directly targets the α subunit of the epithelial sodium channel. Solnatide was shown to have anti-inflammatory actions in acute lung injury and glomerulonephritis models. In this study, we evaluated whether the lectin-like domain of TNF can mitigate the development of immune-mediated arthritis in mice. In an antigen-induced arthritis model, solnatide reduced cell influx and release of pro-inflammatory mediators into the joints, associated with reduction in edema and tissue damage, as compared to controls indicating that TNF has anti-inflammatory effects in an acute model of joint inflammation via its lectin-like domain.

KEYWORDS
arthritis, neutrophils, cytokines, inflammation, tumor necrosis factor
Introduction

Tumor necrosis factor (TNF) is a major cytokine, existing as a transmembrane and soluble ligand, which is involved in various acute and chronic inflammatory diseases. Robust evidence has linked overexpression of TNF to arthritis severity in animal models. TNF inhibitors (TNFi), including neutralizing monoclonal anti-TNF antibodies and soluble TNF receptor constructs, have revolutionized the treatment of rheumatoid arthritis (RA) and spondyloarthritis (SpA) in the clinical setting. TNF is not only a main mediator of pro-inflammatory mediator release, cell migration, and pain development, but the cytokine also activates enzymes that are involved in joint destruction, by eroding cartilage while inducing inflammatory bone resorption (1). Paradoxically, TNF was demonstrated to provide benefit in SpA patients where bone formation rather than erosion ensues, prompting syndesmophyte formation and joint fusion secondary to inappropriate bone formation (2). After cleavage by ADAM17 [A disintegrin and metalloproteinase 17, a.k.a. TNF-alpha converting enzyme (TACE)], the transmembrane form of TNF (tmTNF) is released, generating the soluble TNF (sTNF) ligand. Both TNF forms can bind to both TNF receptors I (RI, 55 kDa) and II (RII, 75 kDa)—with tmTNF having higher affinity for TNF-RI than sTNF—thereby leading to cell death or inflammation (3–6). A marked increase in tmTNF was detected in models of SpA, as compared to RA, correlating with a decrease in the enzymatic activity of ADAM17 (7). These findings suggest that the two TNF forms can induce different activities, despite sharing the same molecular structure and a comparable avidity for TNF RI (7).

In sharp contrast to its deleterious role in numerous pathophysiological phenomena, including the above-described arthropathies, TNF also represents a major component of the first-line defense against invasion by intracellular microorganisms, in addition to its beneficial function in tumor surveillance (8).

The lectin-like domain of TNF, which recognizes specific sugar ligands, such as N,N’-diacetylchitobiose (NAc) and branched trimannoses, is spatially distinct from its receptor binding sites (9, 10). Mapping of the lectin-like domain of TNF was achieved by means of studying the lytic effect of sTNF against bloodstream forms of African trypanosomes (10–12), resulting in the generation of the TNF-derived peptide solnatide (a.k.a. TIP peptide, AP301) with sequence CGQRETPEGAEKPWYC. Although these protozoan parasites lack TNF receptors, TNF was able to kill the parasites via a mechanism involving its lectin-like domain, which can be specifically blocked by the oligosaccharide NAc (10). We have also shown that TNF prevents the formation of *Candida albicans* biofilms, an effect that could be blocked by adding a TNF monoclonal antibody but not the soluble TNF receptor construct etanercept, the latter of which was shown not to interfere with the activity of the lectin-like domain (13).

Interestingly, the isolated addition of NAc specifically blocked the TNF effect on *Candida biofilm* formation, strongly suggesting that TNF was operating *via* its lectin-like domain (14). More recently, it was demonstrated that solnatide improves lung function in acutely inflamed lungs in both animal models of acute respiratory distress syndrome (ARDS) and in ARDS patients (15–18) upon binding to the α subunit of the epithelial sodium channel (ENaC), which can be expressed in both epithelial and endothelial cells (16, 19–22). Solnatide (a.k.a. TIP peptide, AP301) has also been shown to protect kidneys and to exert potent anti-inflammatory activity in an experimental glomerulonephritis model (19). Thus, in addition to different effects of the cytokine dependent on whether tmTNF or sTNF is predominant, TNF might have other activities that are independent of binding to its specific TNF receptors.

Chondrocytes, osteoblasts, and mesenchymal stem cells have been shown to express ENaC-a, to which solnatide binds (22–25). Although the benefit of TNF inhibitors—which block the binding of TNF ligands to their receptors—in treating arthropathies is undisputable, not all patients achieve remission, and there is a risk of increased susceptibility to infection (26), in view of the important role of TNF receptors in host immune defense to invading pathogens. Moreover, some SpA patients hardly display clinically relevant benefit from TNFi administration (27). Hence, in this study, we investigated whether TNF-receptor-independent activities of TNF, such as those mediated by the TNF-derived solnatide peptide, which mimics the lectin-like domain, are protective in an immune-mediated arthritis [methylated bovine serum albumin (mBSA)] mouse model.

Methods

Reagents

All reagents were purchased from Sigma Chem Co., São Paulo, Brazil, unless stated otherwise. Solnatide was kindly donated by Apeptico Forschung und Entwicklung, Vienna, Austria, and was dissolved at the time of use using Roswell Park Memorial Institute (RPMI) 1640 supplemented with L-glutamine.

Animals

A total of 42 Balb-C mice of either sex (25–30 g) were provided by the central animal facilities of our institution. Animals were housed in cages (six per cage) in temperature-
controlled rooms with a 12-h light/dark cycle with free access to water and food. At the start of any experiments, mice were 2.5 months of age. All animal procedures and experimental protocols were approved by our local ethics committee on animal experimentation, which follows the recommendations of the Brazilian Council on Animal Experimentation (CONCEA) (protocol number 113/07). All efforts were made to minimize animal suffering and the number of animals used.

**mBSA arthritis**

Groups of mice received either 500 µg subcutaneous (s.c.) methylated bovine serum albumin (mBSA) s.c. mixed with Freund’s complete adjuvant (immunized) or incomplete Freund’s adjuvant (false-immunized (FI)), followed by a booster injection 7 days later. Twenty-one days following this immunization process, mice received intra-articular (i.a.) 90 µg mBSA. Groups were then sacrificed 7 h (acute phase) or 3 days (chronic phase) following the i.a. mBSA challenge. All injections were done under xylazine (10 mg/kg)/ketamine (80 mg/kg) intra-peritoneal (i.p.) anesthesia, and sacrifice was done under terminal anesthesia.

**Treatments**

In order to investigate the effect of blocking the endogenous lectin-like domain of TNF, groups of mice received 100 µg of NAc in 10 µl saline i.a. or 10 µl saline, 30 min prior to mBSA i.a. In a strategy to evaluate a possible preventive local anti-inflammatory activity of solnatide, groups of naive mice subjected to mBSA arthritis received 10–20 µg of 10 µl i.a. solnatide solutions. As a local therapeutic strategy, another group of mice received 10 µg/10 µl solnatide or 10 µl saline given i.a. 2 days after i.a. challenge with mBSA followed by sacrifice, under terminal anesthesia, after 24 h. In a last set of experiments, as a systemic therapeutic strategy, another group of mice subjected to mBSA arthritis received intravenous (i.v.) solnatide (1–10 µg) immediately prior to i.a. challenge with mBSA.

**Assessment of pain behavior and knee joint swelling**

Nociceptive behavior was assessed using the electronic pressure meter nociception paw test by an observer blinded to group allocation (28). Animals were placed in acrylic cages (12 x 10 x 17 cm high) with a wire grid floor, 15 min before the beginning of the tests, in a quiet room. Stimulation were performed only when animals were quiet, without exploratory, urination, or defecation movements and not resting on their paws. The electronic pressure meter consists of a hand-held force transducer fitted with a polypropylene tip (Electronic von Frey aesthesiometer, Insight Equipamentos Científicos Ltda., Brasil). The polypropylene tip was applied perpendicularly to one of the five distal footpads of the right hind paw. The intensity of the stimulus was automatically recorded when the paw was withdrawn. The test was repeated three times, until less than 1 g difference between measurements was obtained. Results were expressed as the mean value of three withdrawal threshold measurements (g). The diameter of the joints was measured with a caliper (mm), with the whole knee joint swelling determined as the increase in joint diameter. Results were expressed as the Δ (mean variation of three measurements for each joint) relative to baseline.

**Assessment of cell influx and inflammatory mediators in joint exudates**

Animals were sacrificed under anesthesia, and the synovial cavity of the knee joints was washed with 0.05 ml saline containing 10 mmol/L EDTA. Joint washes were collected by aspiration, and total cell counts were performed using a Neubauer chamber. Differential cell counts were performed using the panoptic Instant Prov™ staining kit (New ProvBrasil™). After centrifuging (500 g/10 min), the supernatants were stored at −80°C until used for measuring the concentrations of interleukin (IL)-1β, IL-6, CCL-2, and CXCL1 using commercially available kits (R & D Systems, São Paulo, Brazil).

**Histopathology**

Knee joint tissues were excised for the histological study. After fixation in 10% v/v formaldehyde solution and decalcification (5% v/v formic acid in 10% v/v formaldehyde solution), the whole joint, comprising the distal femoral and proximal tibial extremities, was processed for paraffin-embedding and staining with hematoxylin-eosin (HE) and safranin-O. Analysis was expressed as one result/sample. Semi-quantitative histopathological evaluations were performed by an independent observer (VCCG) blinded to group allocation considering synovial proliferation and cell infiltration and glycosaminoglycan content (safranin staining intensity), ranging from 0 to 3 (0, absent; 1, mild; 2, moderate; 3, severe). Results were expressed as the median value for each group of four animals.

**Statistical analysis**

Results were presented as means ± SD for pain behavior and cell counts in joint washings or medians for histology of measurements made on at least three animals in each group.
Differences between means and medians were compared using Student’s "t" or Mann–Whitney tests, respectively; \( p < 0.05 \) was considered as significant.

**Results**

**Effect of the lectin-like domain inhibitor \(N,N'\)-diacetylcchitobiose in immune-mediated arthritis**

Figure 1 shows that injection of NAc, which binds to the lectin-like domain of TNF (9, 10) into the joints of mice subjected to mBSA arthritis, caused a trend to increased cell counts—albeit not statistically significant—measured after 7 h in joint exudates, with a predominance (>85%) of polymorphonuclear cells (Figures 1A–D). This strategy aimed to determine the effect of specifically blocking the lectin-like domain of TNF released following development of mBSA arthritis. The injection of NAc was also associated with an increase in the levels of pro-inflammatory cytokines and chemokines assayed, although only the increase in IL-1 and CXCL1 reached statistical significance, as compared to levels in animals subjected to mBSA arthritis that received saline (Figures 1E–G). Joint hyper-nociception was not altered in mice subjected to mBSA arthritis that received NAc (Figure 1I).
Effect of a prophylactic intra-articular administration of solnatide in immune-mediated arthritis

Administration of solnatide (10 or 20µg) into the joints of naive mice promoted a mild, acute cell influx, with predominance (>85%) of polymorphonuclear cells, which was similar to that observed in FI animals (Figures 2A–D). Similarly, cytokine and chemokine levels in joint exudates of naive mice that received solnatide did not significantly differ from those observed in FI animals, used as controls (Figures 2E–H). By contrast, the treatment of mice subjected to mBSA arthritis with solnatide significantly reduced cell counts in joint exudates, measured at 7 h after intra-articular challenge (Figures 1A–D). Additionally, levels of pro-inflammatory cytokines and chemokines were also significantly reduced in mice subjected to mBSA arthritis that were treated with solnatide (Figures 2E–H).

Effect of a systemic administration of solnatide in immune-mediated arthritis

Similar to what was seen with the local prophylactic strategy mentioned above, systemic (i.v.) administration of AP301 led to a significant decrease in joint edema and of the acute cell influx into joint exudates, with a decrease in polymorphonuclear cell, lymphocyte, and mononuclear cell counts (Figures 3A–E).

Effect of a therapeutic intra-articular administration of solnatide in immune-mediated arthritis

In order to evaluate the therapeutic potential of the lectin-like domain of TNF, a group of mice subjected to mBSA arthritis received solnatide (10 or 20 µg i.a.) 2 days after intra-articular challenge with mBSA. These mice were sacrificed after 24 h, and the joints were excised for histopathological examination. Results in Figure 4A show a significant reduction in histological scores, followed by representative illustrations of histological sections. Arrows show that staining with safranin O, indicative of glycosaminoglycan content in the cartilage, is reduced in mice subjected to mBSA arthritis treated with saline (Figure 4C), as compared to the joint of a naive animal (Figure 4B). Figure 4D illustrates a partial restoration of staining of the glycosaminoglycans of the joint cartilage in a sample from the group that received solnatide, which means reduced cartilage damage. An extensive cell infiltration and synovial proliferation can also be seen in the sample from animals subjected to mBSA arthritis treated with saline (Figure 4C), which is significantly reduced in the samples from mice treated with solnatide (Figure 4D and Table 1).

Discussion

The development of a synthetic peptide, solnatide (a.k.a. TIP peptide, AP301), which encompasses the amino acid sequence of the lectin-like domain of TNF, is a valuable tool to dissect TNF receptor-dependent from TNF receptor-independent effects. Similar to what happens in the above-described arthropathies, activation of TNF RI has been shown to be crucial to TNF effects in immune glomerulonephritis (29), where it mediates the recruitment of monocytes and activation of mesangial and endothelial cells and podocytes, at least partially via the p38 MAP kinase pathway (19, 30–32). Administration of solnatide (i.p.) significantly reduced inflammation in an experimental glomerulonephritis model, induced by nephrotoxic serum, as it was associated with the reduction in the release of IL-1β and IL-6 and of the chemokines macrophage chemotactic protein (MCP)-1 and keratinocyte-derived chemokine (KC) (19). Similarly, a previous study showed that intratracheal administration of solnatide to rats subjected to acute hypobaric hypoxia followed by exercise reduced pulmonary edema, decreasing alveolar hemorrhage and lung damage. This protective effect was associated with the decreased release of IL-1, IL-6, TNF, and IL-8 into the bronchoalveolar lavage fluid (33).

Our present data for the first time demonstrate that solnatide significantly reduces inflammatory cell infiltration and joint damage in an immune-mediated (mBSA) experimental arthritis model in mice. The effect of solnatide was observed using both prophylactic and therapeutic strategies and following local (intra-articular) and systemic (intravenous) administration. In keeping with data from other studies, solnatide actions were also associated with a reduction in pro-inflammatory cytokine (IL-1β and IL-6) and chemokine (CCL2 and CXCL-1) levels in joint exudates.

The mechanism of action of solnatide involves binding specifically to the C-terminal domain of the α-subunit of the epithelial sodium channel (ENaC) (15, 21, 22). ENaC expression has been demonstrated in a range of epithelial and endothelial cells (15, 16). In joints, ENaC is expressed in chondrocytes and osteoblasts (24, 25). Our observation that solnatide was effective not only when injected locally but also following a systemic prophylactic administration led us to speculate that it operates via resident cells inside the joint. In addition to a rich blood supply, with fenestrated capillaries, the synovial tissue harbors type I, fibroblast-like, and type II, macrophage-like synoviocytes (34). Although chondrocytes and osteoblasts were shown to express ENaC receptors, it is likely that endothelial cells and type II synoviocytes, which were also shown to express ENaC (19, 25), are the primary targets of this peptide following intra-articular injection rather than infiltrating cells, which gain access...
Mice subjected to mBSA arthritis received i.art. solnatide (AP 301) or saline (−) 30 min prior to challenge with mBSA. Cell counts and cytokine and chemokine levels were assayed in joint washes collected after 7 h. FI stands for control, false-immunized animals; *p<0.05 compared to FI; †p<0.05 compared to mBSA, using Student’s ‘t’ test (n≥3 animals/group). (A–D) Total and differential cell counts; (E–H) interleukin (IL-1), IL-6, CXCL-1, and CCL-2 levels.
to the joint approximately 4 h following joint challenge. Additionally, it has been shown that infiltrating leukocytes do not express ENaC (35, 36). Coupling of solnatide to ENaC channels in endothelial cells could reduce inflammation, thereby reducing local edema, as observed in our study. In accordance with our observations in other models of inflammation (19), it is likely that binding of solnatide to ENaC expressed in type II (macrophage-like) synoviocytes would downregulate the release
of pro-inflammatory chemokines and cytokines, thereby reducing cell recruitment and the subsequent release of additional inflammatory mediators. As a result, administration of solnatide would lead to an earlier resolution of inflammation and joint destruction in our immune-mediated arthritis model, as indicated by our present data. A previous study showing that solnatide activates ENaC in mice lacking both TNF receptors (37) and the recent demonstration that depletion of the α subunit of the ENaC blunted the protective effect of solnatide in a TNF-induced inflammation in glomerular endothelial cells (19) led us to propose that there is a high likelihood that solnatide exerts its anti-inflammatory effects in mBSA arthritis via a mechanism independent of the classical TNF receptors but dependent upon the interaction between the lectin-like domain of the cytokine mimicked by solnatide and ENaC. This is substantiated by our observation that treatment with NAc, an oligosaccharide blocking the lectin-like activity of TNF, aggravates pathology.

In summary, these data show that solnatide, a synthetic peptide mimicking the lectin-binding domain of TNF, reduces inflammation in an immune-mediated arthritis model. The anti-inflammatory activity of solnatide is associated with the reduction in joint damage. Since local therapeutic applications of solnatide have already been carried out in humans and have shown to dampen lung inflammation, there is a strong rationale to use solnatide as local treatment in inflammatory arthritis to achieve resolution of arthritis.

### TABLE 1 Histopathological analysis of the effect of solnatide in mBSA arthritis.

| Cell influx | Synovial proliferation | Cartilage damage | Total Score |
|-------------|------------------------|------------------|-------------|
| Naive       | 0 (0–0)                | 0 (0–1)          | 0 (0–0)     |
| NT          | 2.5 (2–3)              | 1 (1–2)          | 2 (2–3)     |
| Solnatide   | 1 (1–2)                | 1 (0–1)          | 1 (1–2)     |
| P value*    | 0.0086                 | 0.0256           | 0.0208      |

Mice subjected to mBSA arthritis received i.art. solnatide (AP 301) or saline (−) 2 days after challenge with mBSA being sacrificed after 24 h; a) Score (medians) of HE and Safranin-O stained whole joints compared using Mann–Whitney; n=6 animals/group; NT, non-treated; p value comparing NT vs Solnatide.
Data availability statement

The original contributions presented in the study are included in the article/supplementary material. Further inquiries can be directed to the corresponding author.

Ethics statement

The animal study was reviewed and approved by Brazilian Council on Animal Experimentation (CONCEA).

Author contributions

FR, FA and GS contributed to the conception of the protocol. FR, RL, AP, IN, VG-C and VO performed animal studies, including histology reading (VG-C). FR, FA and VO performed cytokine measurements. FR, FA, RL, BF and GS wrote the manuscript. All authors contributed to the article and approved the submitted version.

Funding

RL received funding from NIH/NHLBI grant R01 HL138410A; FAA received funding from Fundação de Amparo à Pesquisa de Minas Gerais (FAPEMIG, #APQ-01608-17).

Acknowledgments

We thank Conselho Nacional de Desenvolvimento Científico e Tecnológico (CNPQ)—Brazil for providing partial support for Prof. Rocha. We think Apeptico™ for kindly providing solnatide. We acknowledge partial support of this work from CNPq grants 313860/2021-1 and 403767/2021-0).

Conflict of interest

We received the peptide solnatide from Apeptico as a kind donation but all experiments were run in Brazil Fortaleza and Belo Horizonte and Germany Erlangen. Author BF is an employee of APEPTICO Forschung und Entwicklung. Author RL is an inventor of patents with solnatide.

The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Publisher’s note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.

References

1. McInnes IB, Schett G. Pathogenetic insights from the treatment of rheumatoid arthritis. Lancet. (2017) 389(10086):2328–37. doi: 10.1016/S0140-6736(17)33147-2.
2. Lories RJ, Luypen FP, de Vlam K. Progress in spondylarthritides: mechanisms of new bone formation in spondyloarthritis. Arthritis Res Ther (2009) 11:221. doi: 10.1186/ar2642.
3. Campbell IK, Roberts LJ, Wicks IP. Molecular targets in immune-mediated diseases: the case of tumour necrosis factor and rheumatoid arthritis. Immunol Cell Biol (2003) 81:354–66. doi: 10.1046/j.0818-9641.2003.01185.x.
4. Faustman D, Davis M. TNF receptor 2 pathway: drug target for autoimmune diseases. Nat Rev Drug Discovery (2010) 9:482–93. doi: 10.1038/nrd3030.
5. Fischer R, Marsal J, Guttã c, Eider SA, Peters N, Bettea JB, et al. Novel strategies to mimic transmembrane tumor necrosis factor-dependent activation of tumor necrosis factor receptor 2. Sci Rep (2017) 7:6607. doi: 10.1038/s41598-017-06993-4.
6. Grrell M, Douni F, Wajant H, Lõhden M, Claus M, Maxeiner B, et al. The transmembrane form of tumor necrosis factor is the prime activating ligand of the 80 kDa tumor necrosis factor receptor. Cell. (1995) 83:793–802. doi: 10.1016/0092-8674(95)90192-2.
7. Kaui MH, van Tok MN, Blijdorp JC, Ambarus CA, Stock M, Pots D, et al. Transmembrane TNF drives osteoproliferative joint inflammation reminiscent of human spondyloarthritides. J Exp Med (2020) 217(10):e20200288. doi: 10.1084/jem.20200288.
8. Kalliolias GD, Ivashkiv LB. TNF biology, pathogenic mechanisms and emerging therapeutic strategies nat rev rheumatol. Nat Rev Rheumatol (2015) 12 (1):49–62. doi: 10.1038/nrrheum.2015.169.
9. Hession C, Decker JM, Sherblom AP, Kumar S, Yue CC, Mattaliano RJ, et al. Uremodulin (Tamm-horsfall glycoprotein): a renal ligand for lymphokines. Science. (1987) 237(4821):1479–84. doi: 10.1126/science.3498215.
10. Lucas R, Mager S, De Leys R, Fransen L, Scheerlinck JP, Rampelberg M, et al. Mapping the lectin-like activity of tumor necrosis factor. Science. (1994) 263(5148):814–7. doi: 10.1126/science.8303299.
11. Mager S, Geuskens M, Beschin A, del Forero H, Verschueren H, Lucas R, et al. Specific uptake of tumor necrosis factor-alpha is involved in growth control of trypanosoma brucei. J Cell Biol (1997) 137(3):715–27. doi: 10.1083/jcb.137.3.715.
12. Daoulouide S, Bouteille B, Moynet D, De Baetselier P, Courtois P, Lemere JL, et al. Human macrophage tumor necrosis factor (TNF)-alpha production induced by trypanosoma brucei gambiense and the role of TNF-alpha in parasite control. J Infect Dis (2001) 183(6):988–91. doi: 10.1086/319257.
13. Braun C, Hamacher J, Morel DR, Wendel A, Lucas R. Dichotomal role of TNF in experimental pulmonary edema reabsorption. J Immunol (2005) 175 (3):3402–8. doi: 10.4049/jimmunol.175.5.3402.
14. Rocha FAC, Alves AMCV, Rocha MFG, Cordeiro RA, Brilhante RSN, Pinto ACMd, et al. Tumor necrosis factor prevents candida albicans biofilm formation. Sci Rep (2017) 7(1):1206. doi: 10.1038/s41598-017-01400-4.
15. Czikora I, Alli A, Bao HF, Kaftan D, Sridhar S, Apell HJ, et al. A novel tumor necrosis factor-mediated mechanism of direct epithelial sodium channel activation. Am J Respir Crit Care Med (2014) 190(5):522–32. doi: 10.1164/rccm.201405-0830OC.
16. Czikora I, Alli AA, Sridhar S, Matthy MA, Pillich H, Hudek M, et al. Epithelial sodium channel-ct mediates the protective effect of the TNF-derived TIP.
peptide in pneumolysin-induced endothelial barrier dysfunction. Front Immunol (2017) 8:842. doi: 10.3389/fimmu.2017.00842.

17. Krems K, Lucas R, Croize A, Bohne S, Klein KU, Hermann R, et al. Inhaled AP301 for treatment of pulmonary edema in mechanically ventilated patients with acute respiratory distress syndrome: a phase IIa randomized placebo-controlled trial. Crit Care (2017) 21(1):194. doi: 10.1186/s13054-017-1795-x.

18. Hamacher J, Hadizamani Y, Borgmann M, Mohaupt M, Männel DN, Moehrle V, et al. Cytochrome- Ion Channel Interactions in Pulmonary Inflammation. Front Immunol (2018) 8:1644. doi: 10.3389/fimmu.2017.01644.

19. Madiao MP, Czirka I, Kvirikvelia N, McMenamin M, Yue Q, Liu T, et al. The TNF-derived TIP peptide activates the epithelial sodium channel and ameliorates experimental nephrotic serum nephritis. Kidney Int (2019) 95 (6):1359–72. doi: 10.1016/j.kint.2018.12.022.

20. Sternaã M, Bar A, Adamski MG, Mohaissen T, Marczyk B, Kieronska A, et al. The deletion of endothelial sodium channel a (aENaC) impairs endothelium-dependent vasodilation and endothelial barrier integrity in endotoxemia in vivo. Front Pharmacol (2018) 9:178. doi: 10.3389/fphar.2018.00178.

21. Lucas R, Yue Q, Alii A, Duke BJ, Al-Khalili O, Thai TL, et al. The lectin-like domain of tumor necrosis factor-alpha increases ENaC open probability through a novel site at the interface between the second transmembrane and c-terminal domains of the α-subunit. J Biol Chem (2016) 291(45):23440–51. doi: 10.1074/jbc.M116.718163.

22. Martin-Malpartida P, Arrastia-Casado S, Ferrera-Sinfreu J, Lucas R, Fischer H, Fischer B, et al. Conformational ensemble of the TNF-derived peptide solnatide in solution. Comput Struct Biotechnol J (2022) 20:2082–96. doi: 10.1016/j.csbj.2022.04.031.

23. Kizer N, Guo XL, Hruska K. Reconstitution of stretch-activated cation channels by expression of the alpha-subunit of the epithelial sodium channel cloned from osteoblasts. Proc Natl Acad Sci U.S.A. (1997) 94(3):1013–8. doi: 10.1073/pnas.94.3.1013.

24. Mobasher A, Killick R, Trujillo E, Alvarez de la Rosa D, Marín R, Canessa CM, et al. Subunits of the epithelial sodium channel in avian and human chondrocytes. J Physiol (London) (1999) 518P:117P.

25. Mobasher A, Pocock AE, Trujillo E, Ferraz I, Martin-Vasallo P, Francis MJO. Detection of mRNA and protein of the α subunit of the epithelial sodium channel (ENaC) in human osteoblasts and human ACL cells. J Physiol (2001) 535:4P–5P.

26. Keane J, Gershon S, Wise RP, Mirabâle-Levens R, Kasznica J, Schwietzman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med (2001) 345(15):1098–104. doi: 10.1056/NEJMoa011110.

27. Navarro-Compañ V, Sepriano A, El-Zorkany B, van der Heijde D. Axial spondyloarthritis. Ann Rheum Dis (2021) 80(12):1511–21. doi: 10.1136/annrheumdis-2021-221035.

28. de Melo Nunes R, Cunha PLR, Pinto ACMD, Girão VCC, de Andrade Fettosa JP, Rocha FAC. Hylan G-F20 and galactomannan joint flares are associated to acute synovitis and release of inflammatory cytokines. Adv Rheumatol (2020) 60 (1):26. doi: 10.1186/s42358-020-00127-7.

29. Taubitz A, Schwarz M, Ehrlich N, Lindenmeyer MT, Vielhauer V. Distinct contributions of TNF receptor 1 and 2 to TNF induced glomerular inflammation in mice. PloS One (2013) 8(7):e68167. doi: 10.1371/journal.pone.0068167.

30. Hruby ZW, Shrotor A, Johy S, Lowry RP. Antiserum against tumor necrosis factor alpha and a protease inhibitor reduce immune glomerular injury. Kidney Int (1991) 40(1):43–51. doi: 10.1038/kil.1991.177.

31. Stambe C, Atkins RC, Tesch GH, Kapoun AM, Hill PA. Blockade of p38- or MAPK ameliorates renal injury in rat anti-GBM glomerulonephritis. J Am Soc Nephrol. (2003) 14(2):338–51. doi: 10.1097/01.ASN.0000048715.12315.FD.

32. Timoshanko JR, Sedgwick JD, Holdsworth SR, Tipping PG. Intrinsic renal cells are the major source of tumor necrosis factor contributing to renal injury in murine crescentic glomerulonephritis. FASEB J (2003) 17:858–93. doi: 10.1097/01.ASN.0000073902.38428.33.

33. Zhou Q, Wang D, Liu Y, Yang X, Lucas R, Fischer B. Solnatide demonstrates profound therapeutic activity in a rat model of pulmonary edema induced by acute hypobaric hyperoxia and exercise. Chest. (2017) 151(3):658–67. doi: 10.1016/j.chest.2016.10.030.

34. Németh T, Nagy G, Pap T. Synovial fibroblasts as potential drug targets in rheumatoid arthritis, where do we stand and where shall we go? Ann Rheum Dis (2022) 2022:annrheumdis–2021-222021. doi: 10.1136/annrheumdis-2021-222021.

35. Chopra P, Kanojve V, Semwal A, Ray A. Therapeutic potential of inhaled p38 mitogen-activated protein kinase inhibitors for inflammatory pulmonary diseases. Expert Opin Investig Drugs (2008) 17(10):1411–25. doi: 10.1517/13543784.17.10.1411.

36. Xiao YT, Yan WH, Cao Y, Yan J-K, Cai W. P38 MAPK pharmacological inhibitor SB203580 alleviates total parenteral nutrition-induced loss of intestinal barrier function but promotes hepatocyte lipopoptosis. Cell Physiol Biochem (2017) 41(2):623–34. doi: 10.1159/000457933.

37. Hirbar M, Blec A, van der Goot F, Fransen L, De Baetselier P, Grau GE, et al. The lectin-like domain of tumor necrosis factor-alpha increases membrane conductance in microvascular endothelial cells and peritoneal macrophages. Eur J Immunol (1999) 29(10):3105–11. doi: 10.1002/SICIL20152-4141(199910)29.